Origin and characteristics of an unusual pyridine nucleotide accumulating in erythrocytes: Positive correlation with degree of renal failure

Clinica Chimica Acta

Volumn 335, Issue 1-2, 2003, Pages 117-129

  Carrey, Elizabeth A ^a   Smolenski, Ryszard T ^b,c   Edbury, Stephen M ^a   Laurence, Arian ^d   Marinaki, Anthony M ^a   Duley, John A ^a   Zhu, Limin ^e   Goldsmith, David J A ^a   Simmonds, H Anne ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c HAREFIELD HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Aldehyde oxidase; Dialysis; Molybdenum cofactor; N methylnicotinamide; N1 methyl 2 pyridone 5 carboxamide (M2Py); Renal failure

Indexed keywords

1 METHYL 6 OXONICOTINAMIDE; 2 PYRIDONE 5 CARBOXAMIDE RIBONUCLEOSIDE TRIPHOSPHATE; AMIDE; CREATININE; MOLYBDENUM COMPLEX; N METHYLNICOTINAMIDE; PYRIDINE NUCLEOTIDE; UNCLASSIFIED DRUG; UREMIC TOXIN;

ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ERYTHROCYTE; HALF LIFE TIME; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRECURSOR; PRIORITY JOURNAL; UREMIA;

EID: 0242348794     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00294-8     Document Type: Article

References (31)

1. Horl W.H. Genesis of the uraemic syndrome: role of uraemic toxins. Wien. Klin. Wochenschr. 110:1998;511-520.
2. Asatoor A.M. Retention of pseudouridine and 4-amino-5-imidazole carboxamide in uraemia. Clin. Chim. Acta. 20:1968;407-411.
3. Rejman A.S., Mansell M.A., Grimes A.J., Joekes A.M. Rapid correction of red cell nucleotide abnormalities following successful renal transplantation. Br. J. Haematol. 61:1986;433-443.
4. Simmonds H.A., Fairbanks L.D., Morris G.S., Webster D.R., Harley E.H. Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine and pyrimidine metabolism. Clin. Chim. Acta. 171:1988;197-210.
5. Simmonds H.A., Sahota A., Potter C.F., Perrett D., Hugh-Jones K., Watson J.G. Purine metabolism in adenosine deaminase deficiency. Enzyme defects and immune dysfunction. Ciba Symposium. vol. 68:1979;255-262 Elsevier, Amsterdam. New series.
6. Simmonds H.A., Cameron J.S., Morris G.S., Fairbanks L.D., Davies P.M. Purine metabolites in uraemia. Ringoir S., Vanholder R., Massry S. Uraemic toxins. 1987;73-80 Plenum, New York.
7. Simmonds H.A., Panayi G.S., Corrigall V. A role for purine metabolism in the immune response: adenosine deaminase activity and deoxyadenosine catabolism. Lancet. 1:1978;60-63.
8. Knox W.E., Grossman W.I. A new metabolite of nicotinamide. J. Biol. Chem. 166:1946;391-392.
9. Mrochek J.E., Jolley R.L., Young D.S., Turner W.J. Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin. Chem. 22:1976;1821-1827.
10. Shibata K., Matsuo H. Correlation between niacin equivalent intake and urinary excretion of its metabolites, N′-methylnicotinamide, N′-methyl-2-pyridone-5-carboxamide, and N′-methyl-4-pyridone-5- carboxamide, in humans consuming a self-selected food. Am. J. Clin. Nutr. 50:1989;114-119.
11. Seligson H., Seligson D. N-methyl-2-pyridone-5-carboxylic acid and N-methyl-2-pyridone-5-formamidoacetic acid isolated from dialysis fluids of uremic patients. Clin. Chim. Acta. 12:1965;137-143.
12. Abelson D. Ultra-violet photography of fluorescent spots on chromatograms of biological extracts. Nature. 188:1960;850-851.
13. Kramer B., Seligson H., Seligson D., Baltrush H. Isolation of N-methyl-2-pyridone-5-carboxamide from haemodialysis fluid obtained from uraemic patients. Clin. Chim. Acta. 10:1964;447-452.
14. Chang M.L.W., Johnson B.C. N-methyl-4-pyridone-5-carboxamide as a metabolite of nicotinic acid in man and monkey. J. Biol. Chem. 236:1964;2096-2098.
15. Slominska E.M., Smolenski R.T., Szolkiewicz M., Leaver N., Rutkowski B., Simmonds H.A.et al. Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure. Mol. Cell. Biochem. 231:2002;83-88.
16. Holman W.I.M., Wiegand C. The chemical conversion of nicotinic acid and nicotinamide to derivatives of N-methyl-2-pyridone by methylation and oxidation. Biochem. J. 43:1948;423-426.
17. Bradlow H.L., Vanderwerf C.A. The oxidation of some β-substituted pyridine alkiodides. J. Org. Chem. 16:1951;73-83.
18. Bernofsky C. New synthesis of the 4- and 6-pyridones of 1-methylnicotinamide and 1-methylnicotinic acid (trigonelline). Anal. Biochem. 96:1979;189-200.
19. Simmonds H.A., Duley J.A., Davies P.M. Analysis of purines and pyrimidines in blood, urine and other physiological fluids. Hommes F. Techniques in diagnostic human biochemical genetics: a laboratory manual. 1991;397-424 Wiley-Liss, New York. Chapter 25.
20. Rückemann K., Laurence A., Fairbanks L.D., Harywlowicz K., Richards D., Smolenski R.T.et al. Biochemical basis for the impaired immune response in chronic renal failure? Adv. Exp. Med. Biol. 431:1998;559-563.
21. Duran M., de Bree P.K., de Klerk J.B.C., Dorland L. Molybdenum cofactor deficiency. Clinical presentation and laboratory diagnosis. Int. Pediatr. 11:1996;334-337.
22. Reiter S., Simmonds H.A., Zollner N., Braun S., Knedel M. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol. Clin. Chim. Acta. 187:1990;221-234.
23. Heimberger O. Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis. Kidney Inter., Suppl. 56:1996;S47-S55.
24. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., O'Dea R., Murray D.C. Mode of dialysis therapy and mortality in end-stage renal disease. J. Am. Soc. Nephrol. 9:1998;267-276.
25. Marlewski M., Smolenski R.T., Swierczynski J., Rutkowski B., Duley J.A., Simmonds H.A.et al. Accelerated purine base salvage - a possible cause of elevated nucleotide pool in the erythrocytes of patients with uraemia. Adv. Exp. Med. Biol. 370:1995;19-23.
26. Niwa T., Takeda N., Yoshizumi H. RNA metabolism in uremic patients: accumulation of ribonucleotides in uremic serum. Kidney Int. 53:1998;1801-1806.
27. Heldman D.A., Grever M.R., Miser J.S., Trewyn R.W. Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia. JNCI. 71:1983;269-273.
28. Intrieri M., Calcagno G., Oriani G., Pane F., Zarrilli F., Cataldo P.T. et al. Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in HIV type 1-infected patients are independent predictors for AIDS progression. J. Infect. Dis. 174:1996;199-203.
29. Trewyn R.W., Glaser R., Kelly D.R., Jackson D.G., Graham W.P., Speicher C.E. Elevated nucleoside excretion by patients with nasopharyngeal carcinoma; preliminary diagnostic/prognostic evaluations. Cancer. 49:1982;2513-2517.
30. Schall S. ADP-ribose in DNA repair. ADP-ribosylation reactions. 1982;477-529 Academic Press, New York. Chapter 29.
31. Seto S., Carrera C.J., Wasson D.B., Carson D.A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes. J. Clin. Invest. 75:1985;377-383.